Percheron Therapeutics Ltd (ASX: PER) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Percheron Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.24 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
1.09 billion
Earnings per share
-0.014
Dividend per share
N/A
Year To Date Return
28.57%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Percheron Therapeutics Ltd (ASX: PER)
Latest News
Healthcare Shares
Here's why the Antisense (ASX:ANP) share price is climbing 5% today
Healthcare Shares
Antisense (ASX:ANP) share price accelerates 5% on FDA news
Capital Raising
Antisense Therapeutics (ASX:ANP) share price tumbles 8% amid capital raise
Share Fallers
Here's why the Antisense Therapeutics (ASX:ANP) share price has plummeted 19% on Monday
Healthcare Shares
Why the Antisense (ASX:ANP) share price rocketed 16% today
Share Market News
Why the Antisense (ASX:ANP) share price finished 5% higher today
Healthcare Shares
The Antisense (ASX:ANP) share price is surging 7% today. Here's why
Share Market News
Recent development sends the Antisense (ASX:ANP) share price soaring 45%
PER ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Percheron Therapeutics Ltd
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the ATL1102, and ATL1103 segments. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The ATL1103 segment refers to atesidorsen is an antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin. The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
PER Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Jan 2025 | $0.01 | $0.00 | 0.00% | 1,161,210 | $0.01 | $0.01 | $0.01 |
| 09 Jan 2025 | $0.01 | $0.00 | 0.00% | 20,444,634 | $0.01 | $0.01 | $0.01 |
| 08 Jan 2025 | $0.01 | $0.00 | 0.00% | 3,643,332 | $0.01 | $0.01 | $0.01 |
| 07 Jan 2025 | $0.01 | $0.00 | 0.00% | 5,742,510 | $0.01 | $0.01 | $0.01 |
| 06 Jan 2025 | $0.01 | $0.00 | 0.00% | 59,139,601 | $0.01 | $0.01 | $0.01 |
| 03 Jan 2025 | $0.01 | $0.00 | 0.00% | 21,691,118 | $0.01 | $0.01 | $0.01 |
| 02 Jan 2025 | $0.01 | $0.00 | 0.00% | 9,946,407 | $0.01 | $0.01 | $0.01 |
| 31 Dec 2024 | $0.01 | $0.00 | 0.00% | 14,446,218 | $0.01 | $0.01 | $0.01 |
| 30 Dec 2024 | $0.01 | $0.00 | 0.00% | 2,522,692 | $0.01 | $0.01 | $0.01 |
| 27 Dec 2024 | $0.01 | $0.00 | 0.00% | 20,506,935 | $0.01 | $0.01 | $0.01 |
| 24 Dec 2024 | $0.01 | $0.00 | 0.00% | 10,328,517 | $0.01 | $0.01 | $0.01 |
| 23 Dec 2024 | $0.01 | $0.00 | 0.00% | 35,968,546 | $0.01 | $0.01 | $0.01 |
| 20 Dec 2024 | $0.01 | $0.00 | 0.00% | 25,661,220 | $0.01 | $0.01 | $0.01 |
| 19 Dec 2024 | $0.01 | $0.00 | 0.00% | 35,815,073 | $0.01 | $0.01 | $0.01 |
| 18 Dec 2024 | $0.01 | $-0.05 | -84.75% | 368,947,806 | $0.01 | $0.01 | $0.01 |
| 13 Dec 2024 | $0.06 | $0.00 | 0.00% | 11,186,759 | $0.06 | $0.06 | $0.06 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Dec 2024 | Charmaine Gittleson | Buy | 1,666,666 | $14,999 |
On-market trade.
|
| 24 Dec 2024 | James Garner | Buy | 1,500,000 | $10,500 |
On-market trade.
|
| 20 Dec 2024 | Charmaine Gittleson | Expiry | 6,667 | $46 |
Options expired.
|
| 27 Nov 2024 | James Garner | Buy | 125,000 | $8,937 |
On-market trade.
|
| 25 Nov 2024 | James Garner | Issued | 3,000,000 | $189,000 |
Issue of options.
|
| 25 Nov 2024 | Ben Price | Issued | 3,000,000 | $189,000 |
Issue of options.
|
| 14 Nov 2024 | James Garner | Buy | 375,000 | $30,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Robert William Moses | Non-Executive Director | Oct 2001 |
Mr Moses has more than 40 years of experience in the pharmaceutical/ biotechnology industry. He was formerly Corporate Vice President of CSL Limited. Prior to joining CSL, Mr Moses was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company, and Corporate Manager of New Business Development at ICI (now Orica). Mr Moses is also the former Non-Executive Chairman of TGR Biosciences Pty Ltd. Mr Moses also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly.
|
| Dr Ben Gil Price | Non-Executive Director | Oct 2021 |
Dr Price is an experienced biotech executive and entrepreneur with depth of expertise across clinical asset investment strategy, evaluation, financing and execution. Additional leadership experience includes R&D, Medical, and strategic corporate functions. He is also a member of Governance Committee.
|
| Dr James Garner | Chief Executive OfficerManaging Director | May 2023 |
Dr Garner brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading phase I-IV clinical trials, product registration, reimbursement, and business development.
|
| Dr Charmaine Gittleson | Executive ChairmanExecutive Director | Mar 2021 |
Dr Gittleson has international experience as a pharmaceutical physician and enterprise leader in pharmaceutical drug development, governance and risk management gained during her 15 years of tenure with global specialty biotechnology company CSL Limited. During her time at CSL, Charmaine had at various times accountability for clinical research, medical safety, medical and patient related ethics for development and on market programs, providing leadership in strategic product development, planning and implementation across multiple therapeutic and rare disease areas. She is also a member of Governance Committee.
|
| Ms Deborah Ambrosini | Chief Financial OfficerCompany Secretary | Jun 2024 |
-
|
| Deborah Ambrosini | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 101,082,863 | 11.21% |
| Citicorp Nominees Pty Limited | 31,193,098 | 3.46% |
| Mutual Investments Pty Ltd <Mitchell Family A/C> | 29,848,103 | 3.31% |
| BNP Paribas Nominees Pty Ltd <Clearstream> | 19,776,361 | 2.19% |
| Jamplat Pty Ltd | 15,000,000 | 1.66% |
| Mr Dale Anthony Reed | 13,050,000 | 1.45% |
| Esarad Holdings Pty Ltd | 12,300,888 | 1.36% |
| Citycastle Pty Ltd | 11,688,075 | 1.30% |
| National Nominees Limited | 9,430,584 | 1.05% |
| Mr Robert William Moses | 9,300,000 | 1.03% |
| Mr Robertson Mclennan Mitchell & Mrs Karen Joy Mitchell | 8,455,319 | 0.94% |
| Shared Office Services Pty Ltd <Philanne S/F A/C> | 6,946,304 | 0.77% |
| Mr Jesse Gareth Hedley & Mrs Katie Louise Hedley <Ttm Family A/C> | 6,690,000 | 0.74% |
| Mutual Investments Pty Ltd <The Mitchell Super Fund A/C> | 6,600,000 | 0.73% |
| Mr Glen Stephen Hanly | 6,265,005 | 0.69% |
| Xcelerate Trading Pty Ltd <Xcelerate Trading A/C> | 6,060,000 | 0.67% |
| Mrs Margaret Ann Ryan & Mr Micheal Rodney Ryan | 5,550,000 | 0.62% |
| Kyriaco Barber Pty Ltd | 5,000,000 | 0.56% |
| Mr Mark Diamond | 4,893,722 | 0.54% |
| Statemoor Pty Ltd <Peters Sf A/C> | 4,830,769 | 0.54% |
